A pioneering study by Heffter researcher Matthew Johnson continues to draw attention in the media. A story in the online magazine ATTN covers Johnson’s research on the use of psilocybin for treating nicotine addiction. Writer Kyle Jaeger compares the success rate in Johnson’s study, in which 80 percent of the subjects remained abstinent after six months, with the 30 percent success rate for nicotine replacement and behavioral therapies.
“‘Quitting smoking isn’t a simple biological reaction to psilocybin, as with other medications that directly affect nicotine receptors,’ Dr. Matthew Johnson, the study’s lead author and an associate professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine, wrote. ‘When administered after careful preparation and in a therapeutic context, psilocybin can lead to deep reflection about one’s life and spark motivation to change.’
“Johnson plans to pursue further research into the use of psilocybin to treat smoking addiction, comparing the results to the success of using nicotine patches, and the researchers will ‘use MRI scans to study brain activity in participants.’”
A feature article in the December 2015 issue of Monitor on Psychology, a publication of the American Psychological Association, surveys recent developments in psychedelic science with an emphasis on Heffter-sponsored research. In “One Hit Wonder,” writer Kirsten Weir quotes Heffter researchers Roland Griffiths, Anthony Bossis, and Jeffrey Guss. The article focuses on psilocybin as a treatment for existential distress in cancer patients.
“We don’t deal well with death and dying in this culture,” says Roland Griffiths, PhD, a professor of behavioral biology and neuroscience at the Johns Hopkins University School of Medicine. Being diagnosed with a potentially fatal disease often leads to a kind of chronic syndrome of anxiety, depression and emotional distress. “But under appropriate conditions in well-prepared participants, psilocybin can produce these really quite profound and abrupt shifts in mood and attitude and behavior, even after a single session,” he says. “It’s unlike anything available within psychiatry.”
The States of Consciousness Research Team at Johns Hopkins University is conducting a research study on psychedelic experiences that alter beliefs about death and dying. The study is open to anyone who has had such an experience involving the use of a classic psychedelic such as LSD, psilocybin, mescaline, or DMT. To participate in the study, complete the online Psychedelic Death and Dying Survey. The survey is anonymous and takes about 30 minutes to complete.
The Heffter Research Institute is very grateful to acknowledge a generous financial donation from Breaking Convention, the Conference on Psychedelic Consciousness. At the request of Breaking Convention, their donation will be used to support the NYU clinical trial on psilocybin as a treatment for alcohol addiction.
The California Institute of Integral Studies is offering a training program for medical professionals with an interest in psychedelic research and therapy. The program, which begins in the Spring of 2016, involves 180 hours of academic training with prominent faculty, many of whom are affiliated with the Heffter Research Institute. Graduates of the program receive the Certificate in Psychedelic-Assisted Psychotherapies and Research.
“The Certificate was created to serve a growing need for trained licensed therapist guides to facilitate in future FDA-approved psychedelic- and entactogen-assisted psychotherapy research. Research and medical experts have estimated that need at perhaps several hundred therapist guides in the next three to six years.”
A documentary film titled A New Understanding: The Science of Psilocybin explores the use of psilocybin as a treatment for cancer patients.
“The film presents an intimate look into the lives of several terminally ill cancer patients participating in the studies, and opens an intriguing discourse of the dying process and our role as a society in that process. By informing current misconceptions about psychedelics, A New Understanding utilizes a collection of accomplished minds to discuss psilocybins’ role in culture, evolution, mystical states, and even life itself.”
The New Yorker magazine offers a detailed and insightful examination of Erowid, the online clearing house for information about psychoactive substances. Writer Emily Witt visits the rural California home of Earth and Fire Erowid, the couple behind the hugely successful web site that attracts a broad following of “drug geeks” and medical professionals.
“The average age of Erowid’s thirty thousand Twitter followers is twenty-six. The most frequently looked-at profiles are those of LSD, MDMA, and mushrooms. For years, Erowid’s traffic has declined during school breaks—a gauge of its popularity among eighteen-to-twenty-five-year-olds, the demographic most given to experimenting with drugs. Earth and Fire have spoken before the American Academy of Clinical Toxicology and the National Institute on Drug Abuse, and in 2011 the reform-minded Drug Policy Alliance gave them the Dr. Andrew Weil Award for Achievement in the Field of Drug Education. They have also co-authored several papers in peer-reviewed journals (for example, ‘Use Patterns and Self-Reported Effects of Salvia Divinorum,’ in Drug and Alcohol Dependence) and have collaborated on projects related to such drugs as hallucinogens and opiates with researchers at various institutions, including N.Y.U. and Johns Hopkins.”
In “The Psychedelic Dante,” an article in the February 6, 2015 issue of The American Conservative, writer Rod Dreher discovers parallels between the psychedelic experience and Dante’s Divine Comedy. Dreher begins by noting significant results in current psychedelic science with references to Heffter-supported research by Roland Griffiths, Tony Bossis, and Stephen Ross. Dreher emphasizes the similarity between psychedelic experience and the mystical visions described by Dante.
The Wisconsin Public Radio show “Central Time” recently interviewed two members of the psychedelic research team at the University of Wisconsin School of Pharmacy. (See this blog post for more on the UW study.) Central Time host Veronica Rueckert spoke with Paul Hutson, the lead researcher, and Karen Cooper, the head of the training program for psychedelic guides.
An article on the front page of today’s Wisconsin State Journal covers a a new research study on psilocybin at the University of Wisconsin. In UW Madison tunes in to “magic mushroom” medicine, writer David Wahlberg describes the work of researcher Paul Hutson and his team at the UW School of Pharmacy. Hutson enlisted 12 volunteers for three sessions with psilocybin at doses of 20, 30, and 40 mg per 70 kg of body weight. During each session, the research team collected blood and urine samples to analyze how the body absorbs and eliminates psilocybin. This fundamental research will pave the way for future clinical studies.